OncoCyte (OCX) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OCX shares.
View OCX analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12-month target prices for OncoCyte's shares. Their OCX share price forecasts range from $4.25 to $10.00. On average, they predict the company's share price to reach $7.31 in the next twelve months. This suggests a possible upside of 118.9% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.

OncoCyte's stock was trading at $6.4180 on January 1st, 2023. Since then, OCX shares have decreased by 48.0% and is now trading at $3.34.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our OCX earnings forecast.

OncoCyte Co. (NASDAQ:OCX) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.60) by $1.53. The business earned $0.46 million during the quarter, compared to the consensus estimate of $0.60 million.

OncoCyte shares reverse split before market open on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AWM Investment Company Inc. (172.16%), Pura Vida Investments LLC (165.35%), Geode Capital Management LLC (14.91%), BlackRock Inc. (14.71%), Renaissance Technologies LLC (1.68%) and LPL Financial LLC (1.55%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends.

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCX stock can currently be purchased for approximately $3.34.

OncoCyte (NASDAQ:OCX) has a market capitalization of $27.52 million and generates $960,000.00 in revenue each year.

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.